Serial 97668323
Dead / Abandoned — Abandoned — no statement of use filed (as of 15 Oct 2025)
What this means for you
This application is over — abandoned 15 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97668323
- Mark type
- Design / logo
- Filed
- 08 Nov 2022
- Published for opposition
- 03 Oct 2023
- Abandoned
- 15 Oct 2025
- Attorney of record
- Marie Lavalleye
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products and preparations for the treatment of cancer and auto-immune diseases; Molecules used as a component in pharmaceutical preparations for the treatment of cancer and auto-immune diseases
- Class 042 — Scientific and technological services: Providing medical and scientific research information in the fields of pharmaceuticals, clinical trials, cancer, and auto-immune diseases; Development of molecules for use by others in developing and designing pharmaceutical products and preparations for the treatment of cancer and auto-immune diseases
Owner
- Odyssey Therapeutics, Inc., Boston, MA, US
- Odyssey Therapeutics, Inc., Boston, MA, US
Prosecution history
- 15 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 15 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 22 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Oct 2024 — SOU EXTENSION 2 GRANTED
- 22 Oct 2024 — SOU EXTENSION 2 FILED
- 22 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 30 Jan 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Jan 2024 — SOU EXTENSION 1 GRANTED
- 26 Jan 2024 — SOU EXTENSION 1 FILED
- 26 Jan 2024 — SOU TEAS EXTENSION RECEIVED
- 28 Nov 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Oct 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Oct 2023 — PUBLISHED FOR OPPOSITION
- 13 Sept 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Aug 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER